A phase i trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors

Kyle Holen, Robert DiPaola, Glenn Liu, Antoinette R. Tan, George Wilding, Karl Hsu, Nancy Agrawal, Cong Chen, Lingling Xue, Elizabeth Rosenberg, Mark Stein

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Purpose The kinesin spindle protein (KSP) is essential for separation of spindle poles during mitosis. Its inhibition results in mitotic arrest. This phase I trial examined safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), pharmacokinetic parameters, and anti-tumor activity of MK-0731, a potent inhibitor of KSP. Experimental design In part 1, patients with advanced solid tumors received MK-0731 intravenously over 24 h every 21 days starting at 6 mg/m2, escalating until MTD was reached. In part 2, patients with taxane-resistant tumors received the MTD. Plasma samples were collected to analyze the pharmacokinetics of MK-0731. Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Results In part 1, 21 patients (median age 63 years) were treated with MK-0731 at doses ranging from 6 to 48 mg/m2/24 h for median four cycles. The dose-limiting toxicity was neutropenia and the MTD was 17 mg/m2/24 h. At the MTD, AUC (±SD) was 10.5 (±7.3) μM × hour, clearance (±SD) was 153 mL/min (±84), and t1/2 was 5.9 h. In part 2, 22 patients received the MTD and there were no DLTs. Although there were no objective tumor responses, four patients (with cervical, non-small cell lung, and ovarian cancers) had prolonged stable disease. Conclusions MK- 0731 at the MTD of 17 mg/m2/day every 21 days in patients with solid tumors had few grade 3 and 4 toxicities with the major DLTs at higher doses being myelosuppression. Anti-tumor efficacy was suggested by the length of stable disease in selected patients with taxane-resistant tumors.

Original languageEnglish (US)
Pages (from-to)1088-1095
Number of pages8
JournalInvestigational New Drugs
Volume30
Issue number3
DOIs
StatePublished - Jun 2012

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Keywords

  • Kinesin spindle protein
  • Neutropenia
  • Oncology

Fingerprint Dive into the research topics of 'A phase i trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors'. Together they form a unique fingerprint.

Cite this